For all patients with stage IB-III NSCLC, the pooled OS analysis from eight RCTs with available or updated data showed a significant improvement in long-term survival in the adjuvant EGFR-TKI group compared with the control group in resected EGFR-mutant NSCLC (HR, 0.72; 95% CI, 0.54–0.96, P = 0.024, Fig. 3A). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.